David Tougeron, President of the FFCD Scientific Council, shared a post on LinkedIn:
“Great results of the BOT/BAL combination in chemoresistant pMMR/MSS mCRC with no liver metastase.
- 19% ORR
- 55% DCR
Phase III is ready!”
More posts featuring David Tougeron.
Read the post “No recurrences in MSS colorectal cancer with BOT/BAL neoadjuvant immunotherapy: NEST Trial updates from ASCOGI25” on oncodaily.com.